ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för osimertinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

48 träffar

Bibliografisk träff 2023-12-18

Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.

Guo T, Wu C, Zhang J, Yu J, Li G, Jiang H, Zhang X, Yu R, Liu X.

Cell Commun Signal · video-audio media; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12964-023-01400-0

Bibliografisk träff 2023-08-07

Osimertinib (Tagrisso) for adjuvant treatment of NSCLC.

Författaruppgift saknas

Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1682c

Bibliografisk träff 2023-01-03

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.

Miura S, Koh Y, Azuma K, Yoshioka H, Koyama K, Teraoka S, Ishii H, Kibata K, Ozawa Y, Tokito T, Oyanagi J, Shimokawa T, Kurata T, Yamamoto N, Tanaka H.

BMC Cancer · research-article; clinical trial, phase i; journal article · DOI 10.1186/s12885-022-10467-w

Bibliografisk träff 2023-01-03

Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS.

de Leeuw SP, de Bruijn P, Koolen SLW, Dingemans AC, Mathijssen RHJ, Veerman GDM.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2023.115233

Bibliografisk träff 2023-01-01

Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations.

Mak DY, Tjong MC, Louie AV.

J Thorac Oncol · letter; comment · DOI 10.1016/j.jtho.2022.10.010

Bibliografisk träff 2022-12-28

TAPO in first-line osimertinib therapy and continuation of osimertinib.

Mimura C, Kaneshiro K, Fujimoto S, Dokuni R, Iwamoto N, Matsumura K, Hatakeyama Y, Kono Y, Tachihara M.

Thorac Cancer · research-article; multicenter study; journal article · DOI 10.1111/1759-7714.14782

Bibliografisk träff 2022-12-27

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.

Criscione SW, Martin MJ, Oien DB, Gorthi A, Miragaia RJ, Zhang J, Chen H, Karl DL, Mendler K, Markovets A, Gagrica S, Delpuech O, Dry JR, Grondine M, Hattersley MM, Urosevic J, Floc'h N, Drew L, Yao Y, Smith PD.

NPJ Precis Oncol · research-article; journal article · DOI 10.1038/s41698-022-00337-w

Bibliografisk träff 2022-12-17

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer.

Lee J, Piotrowska Z, Soo R, Cho BC, Lim SM.

Ther Adv Med Oncol · review-article; review; journal article · DOI 10.1177/17588359221144099

Bibliografisk träff 2022-12-10

Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis.

Konishi H, Haga Y, Lin Y, Tsujino H, Higashisaka K, Tsutsumi Y.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2022.12.029

Bibliografisk träff 2022-12-08

Possible heart failure caused by osimertinib in a lung cancer patient.

Ruiz-Briones P, Escudero-Vilaplana V, Collado-Borrell R, Vicente-Valor J, Alvarez R, Villanueva-Bueno C, Narrillos-Moraza Á, Herranz A, Sanjurjo M.

J Oncol Pharm Pract · journal article; case reports · DOI 10.1177/10781552221143787

Bibliografisk träff 2022-11-24

Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP-DRI-12.

Wang L, Fu H, Song L, Wu Z, Yu J, Guo Q, Chen C, Yang X, Zhang J, Wang Q, Duan Y, Yang Y.

Small · research support, non-u.s. gov't; journal article · DOI 10.1002/smll.202204133

Bibliografisk träff 2022-11-03

Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin.

Wu Y, Chen L, Chen J, Xue H, He Q, Zhong D, Diao X.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.122.001019

Bibliografisk träff 2022-11-01

Undertreatment with Osimertinib in patient with multiple chemical sensitivity. A case report.

Gozzi E, Rossi L, Taccogna S, Angelini F.

Clin Ter · journal article; case reports · DOI 10.7417/ct.2022.2472

Bibliografisk träff 2022-10-26

Advanced Lung Cancer Patients' Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada.

Qureshi S, Boily G, Boulanger J, Golo KT, Guédon AC, Lehuédé C, Roussafi F, Truchon C, Strumpf E.

Curr Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/curroncol29110636

Bibliografisk träff 2022-10-17

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.

Wang JL, Wang LS, Zhu JQ, Ren J, Wang D, Luo M.

Respirol Case Rep · journal article; case reports; case-report · DOI 10.1002/rcr2.1054

Bibliografisk träff 2022-10-01

Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With <i>METamp</i> After Osimertinib First-Line Treatment.

Corassa M, Abreu RF, de Lima VCC, Torrezan GT, Cavalher FP, Silva TN, Oliveira TB, Freitas HC, Carraro DM, Costa FD.

JCO Precis Oncol · journal article · DOI 10.1200/po.22.00367

Bibliografisk träff 2022-09-02

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report.

Fukuda Y, Kawa Y, Nonaka A, Shiotani H.

Clin Case Rep · journal article; case reports; case-report · DOI 10.1002/ccr3.6279

Bibliografisk träff 2022-09-01

Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.

Zhao B, Xing H, Ma W.

J Thorac Oncol · letter; comment · DOI 10.1016/j.jtho.2022.06.005

Bibliografisk träff 2022-09-01

[AZD9291 suppresses proliferation and migration of nasopharyngeal carcinoma cells by inhibiting the PI3K-AKT-mTOR pathway].

Zhang H, Pang J, Zhang Y, Ma Y, Fan F, Liu H.

Nan Fang Yi Ke Da Xue Xue Bao · research-article; journal article · DOI 10.12122/j.issn.1673-4254.2022.09.18

Bibliografisk träff 2022-09-01

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.

Chen J, Zhao X, Wang J, Liu F, Zhang L, Chen Y, Chu Q.

Transl Cancer Res · journal article; case reports; case-report · DOI 10.21037/tcr-22-510

Bibliografisk träff 2022-08-07

A Case of Osimertinib-Induced Eosinophilic Pneumonia.

Patel KG, Corbett RL, Karanjawala ZE, Kelly KA, Stollenwerk N, Riess JW.

Clin Lung Cancer · research support, non-u.s. gov't; journal article; case reports · DOI 10.1016/j.cllc.2022.07.013

Bibliografisk träff 2022-07-06

Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.

Cheng YL, Chang WK, Yen H, Peng YJ, Chang WC, Chang PY.

Thorac Cancer · journal article; case reports; case-report · DOI 10.1111/1759-7714.14556

Bibliografisk träff 2022-01-11

Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib.

Mishiro K, Nishii R, Sawazaki I, Sofuku T, Fuchigami T, Sudo H, Effendi N, Makino A, Kiyono Y, Shiba K, Taki J, Kinuya S, Ogawa K.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01211

Bibliografisk träff 2021-10-01

Successful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report.

Li W, He X, Liu H, Zhu J, Zhang HM.

World J Clin Cases · journal article; case reports; case-report · DOI 10.12998/wjcc.v9.i29.8846

Bibliografisk träff 2021-07-21

IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.

Tang X, Mu J, Ma L, Tan Q, Wang J, Tan J, Zhang S.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2021.07.055

Bibliografisk träff 2020-12-17

Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.

Liu Q, Wu L, Zhang S.

Tumori · journal article; case reports · DOI 10.1177/0300891620973262

Bibliografisk träff 2020-10-01

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.

Yu D, Li Y, Sun KD, Gu J, Chen Z, Owonikoko TK, Ramalingam SS, Sun SY.

Am J Cancer Res · research-article; journal article

Bibliografisk träff 2020-06-20

Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis.

Hu X, Chen S, Yin H, Wang Q, Duan Y, Jiang L, Zhao L.

Int J Biol Macromol · journal article · DOI 10.1016/j.ijbiomac.2020.06.154

Bibliografisk träff 2019-09-09

SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.

Tong M, Gao M, Xu Y, Fu L, Li Y, Bao X, Fu H, Quan H, Lou L.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.14180

Bibliografisk träff 2019-03-27

Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.

Assadollahi V, Rashidieh B, Alasvand M, Abdolahi A, Lopez JA.

J Cell Biochem · research support, non-u.s. gov't; journal article · DOI 10.1002/jcb.28575